Review



‒ anti cd44 apc vio779  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Miltenyi Biotec ‒ anti cd44 apc vio779
    ‒ Anti Cd44 Apc Vio779, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 108 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd44+apc/Granzyme+B+Antibody%2C+anti-human%2Fmouse%2Frat%2C+REAfinity/pm42098128-440-54-58
    Average 95 stars, based on 108 article reviews
    ‒ anti cd44 apc vio779 - by Bioz Stars, 2026-09
    95/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: Balancing stromal-induced complexity in 3D ovarian cancer models through heterotypic co-culture with fibroblasts or architected micro-scaffolds.
    Article Snippet: .. Cancer 179 ACCEPTED MANUSCRIPT AR TIC LE IN PR ES S ARTICLE IN PRESS cells were incubated for 20 minutes at 4 °C with the following monoclonal antibodies: ESA (CD326)-PE 180 (Miltenyi Biotec, MACS, clone HEA-125, cat. no. 130-113-826, 1:50), CD44-APC (Miltenyi Biotec, MACS, 181 clone DB105, cat. no. 130-113-893, 1:50), CD90-PE/Cy7 (BioLegend, clone 5E10, cat. no. 328123, 1:25), 182 CD73-PE (BioLegend, clone AD2, cat. no. 344003, 1:25), CD105-APC (BioLegend, clone: 43A3, cat. no. 183 323207, 1:25), and CD155-Pacific Blue (BD Bioscience, clone: SKII.4 and cat. no. 748241, 1:50). ..

    Article Title: Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer.
    Article Snippet: .. Primary antibodies in concentrations according to the manufacturer’s instructions were added: CD326-PE (EpCAM, #130-093-440, Miltenyi Biotec), CD324-APC (E-cadherin, #130-111-993, Miltenyi Biotec), CD44-APC (#130-113-331, Miltenyi Biotec), CD44v6-PE (FAB3660P, R&D Systems, Abingdon, UK), cMET-APC (FAB3582A, R&D Systems), CD325-APC (N-cadherin, #130-116-274, Miltenyi Biotec), CD87-APC (#130-114-893, Miltenyi Biotec), CD338-PE (ABCG2, #12888841, eBiosciences, Altrincham, UK); and incubated for 15 min in the dark. ..

    Article Title: Extended passaging of the SKOV3 ovarian cancer cell line leads to two phenotypically different strains
    Article Snippet: .. Cells were incubated with the following monoclonal antibodies: anti-ESA (CD326)-PE (Miltenyi Biotec, MACS, clone HEA-125, cat. no. 130-113-826, 1:50), CD44-APC (Miltenyi Biotec, MACS, clone DB105, cat. no. 130-113-893, 1:50), CD24-FITC [eBioscienceTM, InvitrogenTM, clone eBioSN3 (SN3 A5-2H10), cat. no. 15576356, 1:20], CD90-PE/Cy7 (BioLegend, clone 5E10, cat. no. 328123, 1:25), CD73-PE (BioLegend, clone AD2, cat. no. 344003, 1:25) and CD274-PE (BD Bioscience, clone MIH1, cat. no. 561787, 1:25). ..

    Bioprocessing:

    Article Title: Balancing stromal-induced complexity in 3D ovarian cancer models through heterotypic co-culture with fibroblasts or architected micro-scaffolds.
    Article Snippet: .. Cancer 179 ACCEPTED MANUSCRIPT AR TIC LE IN PR ES S ARTICLE IN PRESS cells were incubated for 20 minutes at 4 °C with the following monoclonal antibodies: ESA (CD326)-PE 180 (Miltenyi Biotec, MACS, clone HEA-125, cat. no. 130-113-826, 1:50), CD44-APC (Miltenyi Biotec, MACS, 181 clone DB105, cat. no. 130-113-893, 1:50), CD90-PE/Cy7 (BioLegend, clone 5E10, cat. no. 328123, 1:25), 182 CD73-PE (BioLegend, clone AD2, cat. no. 344003, 1:25), CD105-APC (BioLegend, clone: 43A3, cat. no. 183 323207, 1:25), and CD155-Pacific Blue (BD Bioscience, clone: SKII.4 and cat. no. 748241, 1:50). ..

    Article Title: Extended passaging of the SKOV3 ovarian cancer cell line leads to two phenotypically different strains
    Article Snippet: .. Cells were incubated with the following monoclonal antibodies: anti-ESA (CD326)-PE (Miltenyi Biotec, MACS, clone HEA-125, cat. no. 130-113-826, 1:50), CD44-APC (Miltenyi Biotec, MACS, clone DB105, cat. no. 130-113-893, 1:50), CD24-FITC [eBioscienceTM, InvitrogenTM, clone eBioSN3 (SN3 A5-2H10), cat. no. 15576356, 1:20], CD90-PE/Cy7 (BioLegend, clone 5E10, cat. no. 328123, 1:25), CD73-PE (BioLegend, clone AD2, cat. no. 344003, 1:25) and CD274-PE (BD Bioscience, clone MIH1, cat. no. 561787, 1:25). ..

    Magnetic Cell Separation:

    Article Title: Balancing stromal-induced complexity in 3D ovarian cancer models through heterotypic co-culture with fibroblasts or architected micro-scaffolds.
    Article Snippet: .. Cancer 179 ACCEPTED MANUSCRIPT AR TIC LE IN PR ES S ARTICLE IN PRESS cells were incubated for 20 minutes at 4 °C with the following monoclonal antibodies: ESA (CD326)-PE 180 (Miltenyi Biotec, MACS, clone HEA-125, cat. no. 130-113-826, 1:50), CD44-APC (Miltenyi Biotec, MACS, 181 clone DB105, cat. no. 130-113-893, 1:50), CD90-PE/Cy7 (BioLegend, clone 5E10, cat. no. 328123, 1:25), 182 CD73-PE (BioLegend, clone AD2, cat. no. 344003, 1:25), CD105-APC (BioLegend, clone: 43A3, cat. no. 183 323207, 1:25), and CD155-Pacific Blue (BD Bioscience, clone: SKII.4 and cat. no. 748241, 1:50). ..

    Article Title: Extended passaging of the SKOV3 ovarian cancer cell line leads to two phenotypically different strains
    Article Snippet: .. Cells were incubated with the following monoclonal antibodies: anti-ESA (CD326)-PE (Miltenyi Biotec, MACS, clone HEA-125, cat. no. 130-113-826, 1:50), CD44-APC (Miltenyi Biotec, MACS, clone DB105, cat. no. 130-113-893, 1:50), CD24-FITC [eBioscienceTM, InvitrogenTM, clone eBioSN3 (SN3 A5-2H10), cat. no. 15576356, 1:20], CD90-PE/Cy7 (BioLegend, clone 5E10, cat. no. 328123, 1:25), CD73-PE (BioLegend, clone AD2, cat. no. 344003, 1:25) and CD274-PE (BD Bioscience, clone MIH1, cat. no. 561787, 1:25). ..

    Control:

    Article Title: Vitamin B6 Pathway Maintains Glioblastoma Cell Survival in 3D Spheroid Cultures.
    Article Snippet: .. The cell pellets were resuspended and transferred equally into four eppendorf tubes and then mock or control, CD133-PE (Miltenyi Biotec, Bergisch Gladbach, Germany, 130-113-108) and/or CD44-APC (Miltenyi Biotec, 130-113-338) antibody treated for 20 min at 4 ◦C. .. Samples were filtered using a 70 μm filter (FlowmiTM) and 10,000 live cells were analysed using a flow cytometer (BD C6 Accuri) and using FlowJo software (Biosciences, version 10.6.2).

    Article Title: Crosslinking of Ly6a metabolically reprograms CD8 T cells for cancer immunotherapy
    Article Snippet: Intracellular flow cytometry as performed using Miltenyi Biotec fixation buffer and permeabilization buffer according to the manufacture protocol. .. The following antibodies were used: CD4-FITC, mouse (IgG2bκ, Miltenyi Biotec), CD8-APC-VIO770 APC (REA734, Miltenyi Biotec), CD11b-PE (REA592, Miltenyi Biotec), Ly6c-APC (REA796, Miltenyi Biotec), Ly6g-FITC (REA526, Miltenyi Biotec), CD3-VioBlue (BW264/56, Miltenyi Biotec), CD45 APC (REA737, Miltenyi Biotec), Ly6A-PE (REA422, Miltenyi Biotec), CD44 APC (REA664, Miltenyi Biotec), MHC2 APC (M5/114.15.2, Biolegend), CD11c (N418, Biolegend), FoxP3 Alexa fluor 647 (MF-14, Biolegend), CD25 BV650 (PC61, Biolegend), REA control antibody- PE (isotype control, REA293, Miltenyi Biotec), CD69 (clone REA937) and CD62L (clone MEL14-H2.100).H-2Kb:OVA (SINFEKEL) tetramers conjugated to APC were purchased from MBL (Woburn, MA). .. Anti-phopho-Erk1/2 (clone 6B8B69, Biolegend).

    Article Title: Vitamin B6 Pathway Maintains Glioblastoma Cell Survival in 3D Spheroid Cultures
    Article Snippet: .. The cell pellets were resuspended and transferred equally into four eppendorf tubes and then mock or control, CD133-PE (Miltenyi Biotec, Bergisch Gladbach, Germany, 130-113-108) and/or CD44-APC (Miltenyi Biotec, 130-113-338) antibody treated for 20 min at 4 °C. .. Samples were filtered using a 70 μm filter (FlowmiTM) and 10,000 live cells were analysed using a flow cytometer (BD C6 Accuri) and using FlowJo software (Biosciences, version 10.6.2).

    Flow Cytometry:

    Article Title: A multipronged Tα1 reset of CD8 + T cell cytotoxicity against breast cancer.
    Article Snippet: Thymosin α1 (Tα1) is an endogenous thymic peptide that enhances immune competence through activation of T cells, dendritic cells, and innate immune pathways.. However, its direct impact on CD8 T cell–mediated antitumor immunity in breast cancer remains unclear.. In this study, CD8 T cells isolated from peripheral blood of ten healthy donors were cultured under unstimulated, CD3/CD28-stimulated, Tα1-treated, or exhaustion–rescue conditions to evaluate cytotoxic activity against MDA-MB-231 breast cancer cells and CD44 cancer stem-like cells (CD44 CSC-like cells).



    Similar Products

    95
    Miltenyi Biotec ‒ anti cd44 apc vio779
    ‒ Anti Cd44 Apc Vio779, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd44+apc/Granzyme+B+Antibody%2C+anti-human%2Fmouse%2Frat%2C+REAfinity/pm42098128-440-54-58
    Average 95 stars, based on 1 article reviews
    ‒ anti cd44 apc vio779 - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec cd44 apc
    Cd44 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd44+apc/CD326+(EpCAM)+Antibody%2C+anti-human/pm41913277-83-40-41
    Average 95 stars, based on 1 article reviews
    cd44 apc - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec apc anti mouse cd44
    Val-ILs and αPD-1 affect the growth and spread of breast tumor cells 10 6 4T1 cells were transplanted through i.d. injection into the mammary gland of female BALB/c mice. When tumors reached 50 mm 3 , mice were i.v. injected with Val-ILs (10 12 NPs) and i.p. injected with αPD-1 (200 μg) on days 6, 9, and 12. Analyses were performed on day 15 (A–E). (A) Tumor growth volumes measured in vivo. (B) Image of tumors isolated ex vivo from the mammary gland of mice (two independent in vivo experiments). Val-ILs-Combo was efficient in reducing the tumor volumes, and the combination of Val-ILs-Combo and αPD-1 was even more efficient. Mice without breast tumors are identified with a black cross. (C) FC on TAM cells in the TME and macrophages in the spleen, to identify M1-like and M2-like phenotypes. (D) Images of mice measured with in vivo imaging system technology showing the detection of bioluminescent 4T1 cells in the mammary gland, following treatment with Val-ILs-Combo and/or αPD-1. (E) FC was used to detect metastatic <t>CD44</t> + GFP + 4T1 cells spreading to distant organs following treatment. Examples of FC plots and a heatmap displaying the mean percentages. Undetected (ud) indicates the absence of detectable tumor 4T1 cells. (F) On day 30, tumor-free mice were rechallenged with a secondary injection of 10 6 4T1 cells into the contralateral mammary gland. Tumor growth was monitored to evaluate the establishment of a protective anti-tumor memory. The number of mice used per group is indicated on the figure, data are shown as means ± SD, and p values are compared to Val-ILs-IgG + αIgG or between the different groups and are calculated using one-way ANOVA with Tukey’s multiple comparisons test. See also .
    Apc Anti Mouse Cd44, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd44+apc/CD44+Antibody%2C+anti-mouse%2C+REAfinity/pmc13006431-43-0-6
    Average 94 stars, based on 1 article reviews
    apc anti mouse cd44 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    93
    R&D Systems cd44 apc
    Val-ILs and αPD-1 affect the growth and spread of breast tumor cells 10 6 4T1 cells were transplanted through i.d. injection into the mammary gland of female BALB/c mice. When tumors reached 50 mm 3 , mice were i.v. injected with Val-ILs (10 12 NPs) and i.p. injected with αPD-1 (200 μg) on days 6, 9, and 12. Analyses were performed on day 15 (A–E). (A) Tumor growth volumes measured in vivo. (B) Image of tumors isolated ex vivo from the mammary gland of mice (two independent in vivo experiments). Val-ILs-Combo was efficient in reducing the tumor volumes, and the combination of Val-ILs-Combo and αPD-1 was even more efficient. Mice without breast tumors are identified with a black cross. (C) FC on TAM cells in the TME and macrophages in the spleen, to identify M1-like and M2-like phenotypes. (D) Images of mice measured with in vivo imaging system technology showing the detection of bioluminescent 4T1 cells in the mammary gland, following treatment with Val-ILs-Combo and/or αPD-1. (E) FC was used to detect metastatic <t>CD44</t> + GFP + 4T1 cells spreading to distant organs following treatment. Examples of FC plots and a heatmap displaying the mean percentages. Undetected (ud) indicates the absence of detectable tumor 4T1 cells. (F) On day 30, tumor-free mice were rechallenged with a secondary injection of 10 6 4T1 cells into the contralateral mammary gland. Tumor growth was monitored to evaluate the establishment of a protective anti-tumor memory. The number of mice used per group is indicated on the figure, data are shown as means ± SD, and p values are compared to Val-ILs-IgG + αIgG or between the different groups and are calculated using one-way ANOVA with Tukey’s multiple comparisons test. See also .
    Cd44 Apc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd44+apc/Human+CD44+v6+PE-conjugated+Antibody/pm41631682-53-21-27
    Average 93 stars, based on 1 article reviews
    cd44 apc - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec apc anti cd44
    Val-ILs and αPD-1 affect the growth and spread of breast tumor cells 10 6 4T1 cells were transplanted through i.d. injection into the mammary gland of female BALB/c mice. When tumors reached 50 mm 3 , mice were i.v. injected with Val-ILs (10 12 NPs) and i.p. injected with αPD-1 (200 μg) on days 6, 9, and 12. Analyses were performed on day 15 (A–E). (A) Tumor growth volumes measured in vivo. (B) Image of tumors isolated ex vivo from the mammary gland of mice (two independent in vivo experiments). Val-ILs-Combo was efficient in reducing the tumor volumes, and the combination of Val-ILs-Combo and αPD-1 was even more efficient. Mice without breast tumors are identified with a black cross. (C) FC on TAM cells in the TME and macrophages in the spleen, to identify M1-like and M2-like phenotypes. (D) Images of mice measured with in vivo imaging system technology showing the detection of bioluminescent 4T1 cells in the mammary gland, following treatment with Val-ILs-Combo and/or αPD-1. (E) FC was used to detect metastatic <t>CD44</t> + GFP + 4T1 cells spreading to distant organs following treatment. Examples of FC plots and a heatmap displaying the mean percentages. Undetected (ud) indicates the absence of detectable tumor 4T1 cells. (F) On day 30, tumor-free mice were rechallenged with a secondary injection of 10 6 4T1 cells into the contralateral mammary gland. Tumor growth was monitored to evaluate the establishment of a protective anti-tumor memory. The number of mice used per group is indicated on the figure, data are shown as means ± SD, and p values are compared to Val-ILs-IgG + αIgG or between the different groups and are calculated using one-way ANOVA with Tukey’s multiple comparisons test. See also .
    Apc Anti Cd44, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd44+apc/CD44+Antibody%2C+anti-human/pmc12757047-266-19-21
    Average 95 stars, based on 1 article reviews
    apc anti cd44 - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    93
    Cytek Biosciences cd44 apc cy7
    Val-ILs and αPD-1 affect the growth and spread of breast tumor cells 10 6 4T1 cells were transplanted through i.d. injection into the mammary gland of female BALB/c mice. When tumors reached 50 mm 3 , mice were i.v. injected with Val-ILs (10 12 NPs) and i.p. injected with αPD-1 (200 μg) on days 6, 9, and 12. Analyses were performed on day 15 (A–E). (A) Tumor growth volumes measured in vivo. (B) Image of tumors isolated ex vivo from the mammary gland of mice (two independent in vivo experiments). Val-ILs-Combo was efficient in reducing the tumor volumes, and the combination of Val-ILs-Combo and αPD-1 was even more efficient. Mice without breast tumors are identified with a black cross. (C) FC on TAM cells in the TME and macrophages in the spleen, to identify M1-like and M2-like phenotypes. (D) Images of mice measured with in vivo imaging system technology showing the detection of bioluminescent 4T1 cells in the mammary gland, following treatment with Val-ILs-Combo and/or αPD-1. (E) FC was used to detect metastatic <t>CD44</t> + GFP + 4T1 cells spreading to distant organs following treatment. Examples of FC plots and a heatmap displaying the mean percentages. Undetected (ud) indicates the absence of detectable tumor 4T1 cells. (F) On day 30, tumor-free mice were rechallenged with a secondary injection of 10 6 4T1 cells into the contralateral mammary gland. Tumor growth was monitored to evaluate the establishment of a protective anti-tumor memory. The number of mice used per group is indicated on the figure, data are shown as means ± SD, and p values are compared to Val-ILs-IgG + αIgG or between the different groups and are calculated using one-way ANOVA with Tukey’s multiple comparisons test. See also .
    Cd44 Apc Cy7, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd44+apc/APC-Cyanine7+Anti-Human%2FMouse+CD44/pm41094529-56-23-24
    Average 93 stars, based on 1 article reviews
    cd44 apc cy7 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    Val-ILs and αPD-1 affect the growth and spread of breast tumor cells 10 6 4T1 cells were transplanted through i.d. injection into the mammary gland of female BALB/c mice. When tumors reached 50 mm 3 , mice were i.v. injected with Val-ILs (10 12 NPs) and i.p. injected with αPD-1 (200 μg) on days 6, 9, and 12. Analyses were performed on day 15 (A–E). (A) Tumor growth volumes measured in vivo. (B) Image of tumors isolated ex vivo from the mammary gland of mice (two independent in vivo experiments). Val-ILs-Combo was efficient in reducing the tumor volumes, and the combination of Val-ILs-Combo and αPD-1 was even more efficient. Mice without breast tumors are identified with a black cross. (C) FC on TAM cells in the TME and macrophages in the spleen, to identify M1-like and M2-like phenotypes. (D) Images of mice measured with in vivo imaging system technology showing the detection of bioluminescent 4T1 cells in the mammary gland, following treatment with Val-ILs-Combo and/or αPD-1. (E) FC was used to detect metastatic CD44 + GFP + 4T1 cells spreading to distant organs following treatment. Examples of FC plots and a heatmap displaying the mean percentages. Undetected (ud) indicates the absence of detectable tumor 4T1 cells. (F) On day 30, tumor-free mice were rechallenged with a secondary injection of 10 6 4T1 cells into the contralateral mammary gland. Tumor growth was monitored to evaluate the establishment of a protective anti-tumor memory. The number of mice used per group is indicated on the figure, data are shown as means ± SD, and p values are compared to Val-ILs-IgG + αIgG or between the different groups and are calculated using one-way ANOVA with Tukey’s multiple comparisons test. See also .

    Journal: Cell Reports Medicine

    Article Title: Valrubicin-loaded immunoliposomes targeting antigens on immunosuppressive cells to circumvent resistance to cancer immunotherapy

    doi: 10.1016/j.xcrm.2026.102632

    Figure Lengend Snippet: Val-ILs and αPD-1 affect the growth and spread of breast tumor cells 10 6 4T1 cells were transplanted through i.d. injection into the mammary gland of female BALB/c mice. When tumors reached 50 mm 3 , mice were i.v. injected with Val-ILs (10 12 NPs) and i.p. injected with αPD-1 (200 μg) on days 6, 9, and 12. Analyses were performed on day 15 (A–E). (A) Tumor growth volumes measured in vivo. (B) Image of tumors isolated ex vivo from the mammary gland of mice (two independent in vivo experiments). Val-ILs-Combo was efficient in reducing the tumor volumes, and the combination of Val-ILs-Combo and αPD-1 was even more efficient. Mice without breast tumors are identified with a black cross. (C) FC on TAM cells in the TME and macrophages in the spleen, to identify M1-like and M2-like phenotypes. (D) Images of mice measured with in vivo imaging system technology showing the detection of bioluminescent 4T1 cells in the mammary gland, following treatment with Val-ILs-Combo and/or αPD-1. (E) FC was used to detect metastatic CD44 + GFP + 4T1 cells spreading to distant organs following treatment. Examples of FC plots and a heatmap displaying the mean percentages. Undetected (ud) indicates the absence of detectable tumor 4T1 cells. (F) On day 30, tumor-free mice were rechallenged with a secondary injection of 10 6 4T1 cells into the contralateral mammary gland. Tumor growth was monitored to evaluate the establishment of a protective anti-tumor memory. The number of mice used per group is indicated on the figure, data are shown as means ± SD, and p values are compared to Val-ILs-IgG + αIgG or between the different groups and are calculated using one-way ANOVA with Tukey’s multiple comparisons test. See also .

    Article Snippet: APC anti-Mouse CD44 (Clone REA664) , Miltenyi Biotec , Cat# 130-119-121; RRID: AB_2751628.

    Techniques: Injection, In Vivo, Isolation, Ex Vivo, In Vivo Imaging